CliffBio
small molecule

TRADJENTA

LINAGLIPTIN

Loss of exclusivityDecember 2037latest FDA-listed patent expiry
CompanyBoehringer Ingelheim →See this company's full patent-cliff portfolio

Drug detail

Brand nameTRADJENTA
Active ingredientLINAGLIPTIN
Strength5MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2011
Marketing statusRX

Listed patents

PatentExpiresType
12364700*PEDDecember 2037—
12364700June 2037use U-4224
8853156*PEDSeptember 2031—
8853156March 2031product
8846695*PEDDecember 2030—
8846695June 2030use U-1503
11911388April 2030use U-3854
10034877*PEDFebruary 2030—
9486526*PEDFebruary 2030—
10034877August 2029use U-2347
9486526August 2029use U-1915
11033552*PEDNovember 2027—
8673927*PEDNovember 2027—
8673927May 2027use U-1503
12178819May 2027product
11033552May 2027product
8883805*PEDMay 2026—
8883805November 2025product

Regulatory exclusivity

CodeExpires
PEDDecember 2026
M-295June 2026

More from Boehringer Ingelheim

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TRADJENTA patent cliff — loss of exclusivity December 2037 | CliffBio